Delivery Order SPE2DB20D2104-SPE2DB24FS65Y

Award Date 2/20/24
Potential Completion Date 2/21/24
Potential Value $3K
Ultimate Awardee
Cencora, Inc.
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $11,981.04, is a delivery order for the supply of Restasis 0.05% Eye Emulsion. This award is part of a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Restasis 0.05% Eye Emulsion 30s. The $2,853.54 firm fixed-price delivery order is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that Amerisourcebergen holds with the DLA Troop Support Medical. This IDC serves as the primary vehicle for the company to provide a comprehensive range of...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of Restasis 0.05% eye emulsion. The $16,124.33 firm fixed-price delivery order is a component of a larger $999,999,999.00 Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical. This IDC serves as the primary vehicle for Amerisourcebergen to provide a...
This federal contract award is a delivery order valued at $2,352.00 issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of RESTASIS 0.05% eye emulsion, a prescription ophthalmic medication. The award is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $5,023.80 firm fixed-price delivery order (SPE2DB22FN07L) is for the supply of Restasis 0.05% eye emulsion to support military treatment facilities and federal healthcare programs. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves...
This federal contract award, valued at $2,186.01, was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract provides for the delivery of Restasis 0.05% eye emulsion, a specialty ophthalmology medication, to support military and federal healthcare programs. The award is a firm-fixed-price delivery order, issued under Amerisourcebergen's existing Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which has a...
This federal contract award to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, involves the delivery of Restasis 0.05% eye emulsion to the Defense Logistics Agency (DLA) Troop Support Medical. The $1,080.48 firm fixed-price delivery order is placed against an Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that AmerisourceBergen holds with the DLA. This IDC serves as a primary vehicle for the company to provide a comprehensive range of pharmaceutical...
This federal contract award to Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc., is a delivery order valued at $1,800.80 for the supply of Restasis 0.05% eye emulsion. The contract was awarded by the Defense Logistics Agency (DLA), a defense agency, and has no set-aside designation. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical that serves as the primary vehicle for the company to provide a comprehensive range...
This federal contract award was made by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corporation's Corporate Office division, a major pharmaceutical distributor, to provide Restasis 0.05% eye emulsion. The contract has a ceiling value of $24,566.07 and is a firm fixed-price delivery order, without a set-aside designation. Amerisourcebergen holds a substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued up to $999,999,999.00 through December 2025,...
This federal contract award, valued at $16,992.30, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the delivery of RESTASIS 0.05% eye emulsion. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA Troop Support Medical, valued at up to $999,999,999.00 through November 2026. This IDC serves as the primary vehicle for...
  • SPE2DB20D2104
    Indefinite Delivery Contract
  • SPE2DB20D2104-SPE2DB24FS65Y
    Delivery Order

This federal contract award, valued at $3,020.16, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, which is a delivery order, is for the supply of Restasis 0.05% eye emulsion. This award is part of a larger Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at up to $999,999,999.00 and running through November 2026. This IDC serves as the primary vehicle for Amerisourcebergen to deliver a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract award does not have a set-aside designation, indicating open competition. Amerisourcebergen's parent company is Cencora, Inc., which also holds a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000 through May 2024, for similar medical products and prescription drugs.

Generated 2/27/25, 10:44 AM